368 related articles for article (PubMed ID: 27184755)
1. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
Huang H; Weng J; Wang MH
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
[TBL] [Abstract][Full Text] [Related]
2. Diabetic CVD--soluble epoxide hydrolase as a target.
Lorthioir A; Guerrot D; Joannides R; Bellien J
Cardiovasc Hematol Agents Med Chem; 2012 Sep; 10(3):212-22. PubMed ID: 22632263
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
4. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.
Theken KN; Schuck RN; Edin ML; Tran B; Ellis K; Bass A; Lih FB; Tomer KB; Poloyac SM; Wu MC; Hinderliter AL; Zeldin DC; Stouffer GA; Lee CR
Atherosclerosis; 2012 Jun; 222(2):530-6. PubMed ID: 22503544
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation.
Deng Y; Theken KN; Lee CR
J Mol Cell Cardiol; 2010 Feb; 48(2):331-41. PubMed ID: 19891972
[TBL] [Abstract][Full Text] [Related]
7. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model.
Chen L; Fan C; Zhang Y; Bakri M; Dong H; Morisseau C; Maddipati KR; Luo P; Wang CY; Hammock BD; Wang MH
Prostaglandins Other Lipid Mediat; 2013; 104-105():42-8. PubMed ID: 23247129
[TBL] [Abstract][Full Text] [Related]
9. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
[TBL] [Abstract][Full Text] [Related]
10. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
11. Beyond detoxification: a role for mouse mEH in the hepatic metabolism of endogenous lipids.
Marowsky A; Meyer I; Erismann-Ebner K; Pellegrini G; Mule N; Arand M
Arch Toxicol; 2017 Nov; 91(11):3571-3585. PubMed ID: 28975360
[TBL] [Abstract][Full Text] [Related]
12. The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Xu X; Li R; Chen G; Hoopes SL; Zeldin DC; Wang DW
Adv Nutr; 2016 Nov; 7(6):1122-1128. PubMed ID: 28140329
[TBL] [Abstract][Full Text] [Related]
13. Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy.
Maayah ZH; McGinn E; Al Batran R; Gopal K; Ussher JR; El-Kadi AOS
J Cardiovasc Pharmacol; 2019 Sep; 74(3):235-245. PubMed ID: 31306370
[TBL] [Abstract][Full Text] [Related]
14. Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl/6 mouse heart.
Amara IE; Elshenawy OH; Abdelrady M; El-Kadi AO
Toxicol Lett; 2014 Apr; 226(1):53-62. PubMed ID: 24472606
[TBL] [Abstract][Full Text] [Related]
15. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.
Diani-Moore S; Ma Y; Gross SS; Rifkind AB
Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719
[TBL] [Abstract][Full Text] [Related]
16. Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer.
Wei X; Zhang D; Dou X; Niu N; Huang W; Bai J; Zhang G
BMC Cancer; 2014 Nov; 14():841. PubMed ID: 25406731
[TBL] [Abstract][Full Text] [Related]
17. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.
Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X
Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225
[TBL] [Abstract][Full Text] [Related]
18. Postprandial effect to decrease soluble epoxide hydrolase activity: roles of insulin and gut microbiota.
Yang J; Oh YT; Wan D; Watanabe RM; Hammock BD; Youn JH
J Nutr Biochem; 2017 Nov; 49():8-14. PubMed ID: 28863368
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response.
Nayeem MA; Hanif A; Geldenhuys WJ; Agba S
Pharmacol Ther; 2022 Dec; 240():108213. PubMed ID: 35597366
[TBL] [Abstract][Full Text] [Related]
20. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]